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David J. Erie,* Michael A. Matthay,*82 Jeanine P Wiener-Kronish,*~ 
and Richard M. Locksley*ll 
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Summary 
Reversible airway hyperreactivity underlies the pathophysiology of asthma, yet the precise me- 
diators of the response remain unclear. Human studies have correlated aberrant activation of T 
helper (Th) 2-like effector systems in the airways with disease. A routine model of airway hy- 
perreactivity in response to acetylcholine was established using mice immunized with ovalbu- 
rain and challenged with aerosolized antigen. No airway hyperreactivity occurred in severe 
combined immunodeficient mice. Identically immunized BALB/c mice developed an influx of 
cells, with a predominance of eosinophils and CD4 + T cells, into the lungs and bronchoalveo- 
lar lavage fluid at the time that substantial changes in airway pressure and resistance were quan- 
titated. Challenged animals developed marked increases in Th2 cytokine production, eosino- 
phil influx, and serum immunoglobulin E levels. Neutralization of interleukin (IL) 4 using 
monoclonal antibodies administered during the period of systemic immunization abrogated air- 
way hyperreactivity but had little effect on the influx of eosinophils. Administration of anti- 
IL-4 only during the period of the aerosol challenge did not affect he subsequent response to 
acetylcholine. Finally, administration of anti-IL-5 antibodies at levels that suppressed eosino- 
phils to < 1% of recruited cells had no effect on the subsequent airway responses. BALB/c mice 
had significantly greater airway responses than C57BL/6 mice, consistent with enhanced IL-4 
responses to antigen in BALB/c mice. Taken together, these data implicate IL-4 generated 
during the period of lymphocyte priming with antigen in establishing the cascade of responses 
required to generate airway hyperreactivity to inhaled antigen. No role for IL-5 or eosinophils 
could be demonstrated. 
A sthma is one of the common chronic lung diseases of industrialized countries. Despite ffective therapy, treat- 
ment costs, toxicity, and the need for coordinated delivery 
of medication limit the benefits of current regimens. Strate- 
gies designed to prevent asthma in high-risk individuals, or 
that reverse the pathologic processes that lead to asthma, 
could be far more effective than current interventions. Un- 
fortunately, development of such strategies has been ham- 
pered by a lack of basic understanding of the pathogenesis 
of the disease. 
Reversible airway narrowing, the physiologic hallmark 
of asthma, is often seen in association with evidence of im- 
mune system activation, including T cell and eosinophil n- 
filtration of the airways. Evidence for Th2 cytokine pro- 
duction, including IL-4 and IL-5, and effector function, 
such as eosinophil nfiltration and elevated levels of IgE, has 
been reported (1-8). A number of secondary inflammatory 
mediators, particularly mast cell and eosinophil products, 
have been shown to induce physiologic hanges imilar to 
asthma or to cause smooth muscle contraction i  vitro (9, 
10). However, little direct experimental evidence exists 
that clearly identifies the principal pathogenic cells and me- 
diators of this complex inflammatory cascade. 
Murine models of airway hyperreactivity have been used 
to begin to identify components of the immune response, 
although the imanunology, cellular response, and airway 
physiology have infrequently been coordinately investi- 
gated (11-18). We have established a murine model and 
used this to elucidate critical cellular and cytokine require- 
ments for the acute airway changes induced by exposure to 
antigen. Surprisingly, these data fail to support a role for 
two prominent components of the inflammatory esponse, 
eosinophils and IL-5, and emphasize the need for integra- 
tion of immunologic and physiologic studies. 
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Materials and Methods 
Immunization Protocol. BALB/c, C57BL/6, and C.B-17/scid 
mice were purchased from the Jackson Laboratory (Bar Harbor, 
ME). Mice were inmmnized with 25 ~g turkey egg OVA (Sigma 
Chemical Co., St. Louis, MO) adnfinistered subcutaneously with 
alum weekly for 4 wk and subsequently exposed to two or three 
aerosolizations 5 d apart of OVA or an unrelated immunodomi- 
nant antigen from the protozoan Leishmania major (19). Aero- 
solization of antigens was performed using a nose-only aerosol 
chamber adapted for mice (Intox Products, Albuquerque, NM) 
coupled to a nebulizer (Aerotech II; CIS-US, Bedford, MA) 
driven by compressed air at a flow rate of 10 liters/min. Under 
these conditions, aerosol particles have a median aerodynamic di- 
ameter of 1.4 0.m as measured by a cascade impactor (Intox Prod- 
ucts). Antigen was delivered over 20 min at a concentration f 50 
rag/nil in PBS. Designated groups of mice received Img neutral- 
izing anti-lL-4 mAb (11B11; rat IgG1; reference 20) intraperito- 
neally weekly, either throughout the experimental protocol or 
limited to the aerosolization period, as denoted; or a combination 
of 1 ~Lg each of two neutralizing anti-IL-5 mAbs (TRFK-4 and 
TILFK-5; rat lgG2a and IgGl, respectively; reference 21) intra- 
peritoneally weekly throughout the experimental period, lsotype 
control antibodies Y13-259 (rat lgG1) and u (rat lgG2a) 
were adnfinistered to control groups. 
Determination ofAinvay Phj,siology. 24 h after the final aerosol 
exposure, mice were anesthetized with pentobarbital (Abbott 
Laboratories, North Chicago, IL; 50 mg/kg intraperitoneally) and 
the tracheas were surgically exposed, cannulated, and connected 
to a rodent ventilator (Harvard Apparatus, South Natick, MA) with 
an in-line pressure transducer (Pd23 inside diameter; Gould, Inc., 
Oxnard, CA). Animals were ventilated with 100% oxygen (9 ~1/ 
g) at 120 breaths/min; under these conditions, naive mice main- 
tain physiologic arterial blood gas parameters except for supra- 
physiologic arterial Pao 2 (data not shown). A paralytic agent (pan- 
curonium bromide, 0.1 mg/kg; Gensia Laboratories, lrvine, CA) 
was administered to eliminate spontaneous respirations. After re- 
cording of a stable baseline airway pressure (<5% variation over 3 
min), acetylcholine chloride (Ach; 1 btg/g; Signaa Chemical Co.) 
was infused intravenously over I s via the tail vein and the change 
in airway pressure recorded over 3 min on a standard polyg-raph 
(Grass Instrument Co., Quincy, MA). Final airway pressure changes 
were recorded as the maximum percentage of change in airway 
pressure from baseline (maximum airway pressure - baseline air- 
way pressure/baseline airway pressure). 
To compare changes in airway pressure, as measured above, 
with changes in resistance, separate groups of comparably treated 
mice were analyzed using a protocol modified from Amdur and 
Mead (22). Mice were anesthetized and ventilated as above, and a 
27-guage needle was used to establish intravenous access in the 
tail vein. Animals were placed inside a plethysmograph coupled to 
a pressure transducer (model MP45; Validyne Engineering Corp., 
Northridge, CA) and constructed with ports for intravenous and 
ventilator access tubing. Lung resistance (R,~) was determined by 
continuously quantitating the quotient APt/AV (where APt = 
change in tracheal pressure and AV = change in flow) at points of 
equal lung volume (70% tidal volume) using a pulmonary me- 
chanics analyzer (model 6; Buxco Corp., Sharon, CT). APt was 
determined using a pressure transducer (model 267 BC; Sanborn 
Co., Waltham, MA) connected to the tracheal cannnla. To deter- 
mine AV, plethysmograph ressure changes were calibrated to 
changes in volume over the physiologic range studied. The dif- 
ferential of this value over time is ?iV. After establishing a stable 
baseline tk~ (<5% variation over 3 rain), Ach was administered 
intravenously over 1 s in increasing doses until at least a 50% in- 
crease in airway pressure and a 200% increase in R~ was obtained. 
The provocative concentration of Ach, in micrograms Ach per 
gram, that caused a 50% increase in airway pressure (PCs0) and a 
200% increase in 1L L (PC200) was calculated from interpolation of 
appropriate dose-response curves as described (23). 
Collection of Lung Cells. Immediately after collection of physi- 
ologic parameters, mice were given 0.1 ml 1:1,000 heparin intra- 
peritoneally and killed by transecting the let~ renal artery for col- 
lection of blood. Bronchoalveolar lavage (BAL) I cells were 
collected by lavaging whole lung with 3 ml PBS in 0.5-nil ali- 
quots via the tracheal cannula nd withdrawing slowly while gently 
massaging the thorax. Whole-lung cells were prepared after re- 
moving residual blood by thorough perfusion of PBS via the 
main puhnonary artery until the lungs were completely blanched. 
The lungs were removed and minced into fine fragments that 
were gently dispersed into PBS using a syringe plunger and passed 
through a 0.75-bml nylon mesh filter. BAL and whole lung cells 
were washed twice, counted, and resuspended at 107 cells/nil in 
RPMI-1640 with 5% fetal bovine serum (FBS; Hyclone Labora- 
tories Inc., Logan, UT) and antibiotics. 
Analysis of Cytokine Transcripts. Cells were lysed in RNAzol 
B (Biotecx Laboratories, Houston, TX) and RNA extracted ac- 
cording to the manufacturer's ecommendations. RNA was re- 
verse transcribed with Moloney murine leukemia virus reverse 
transcriptase (GIBCO BRL, Gaithersburg, MD) and random 
hexamer primers (Promega Corp., Madison, WI). PCtL was per- 
formed with a multiple cytokine competitor construct as de- 
scribed (24). The construct contains a sequence specific for the 
constitutively expressed gene encoding hypoxanthine phosphori- 
bosyltransferase (HP1LT), allowing adjustments of input cDNA to 
comparable amounts of HPtLT expression. Adjusted cDNAs were 
then amplified with cytokine-specific primers, and the products 
were separated by electrophoresis in ethidium bromide-stained 
2.5% agarose gels, thus allowing discrimination of the larger coin- 
petitor construct from the wild-D,pe cDNAs that migrate further 
in the gel. Photographic negatives of the gels were scanned with 
an imaging densitometer to quantitate band intensities and con- 
firm visual interpretations. 
FACS | Analysis. 10 s cells were stained with PE-conjugated 
anti-CD4, FITC-conjugated anti-CD8, and FITC-conjugated anti- 
B220 mAbs (PharMingen, San Diego, CA) and analyzed for sur- 
face expression by cytofluorimetry (FACScan| Becton Dickin- 
son 8: Co., Mountain View, CA). 
Cell Differentials. 1-5 • 103 cells were spun onto glass slides 
(Cytospin 2; Shandon Instruments, Inc., Astmoor, UK), air dried, 
fixed with methanol, and stained with Diff-Quik (Baxter Health- 
care Corp., Miami. FL). Eosinophils and macrophages/mono- 
cytes were enumerated based on nmrphology and staining char- 
acteristics and expressed as percentages of total cells. Eosinophil 
counts were confirmed with phloxine B staining (Unopette; 
Beckton Dickinson & Co.). 
ELISPOT Assa},s. Single-cell suspensions from whole lung 
cells were distributed in duplicate aliquots (10 ~ cells in 100 ILl of 
RPMI-1640 with 5% FBS and antibiotics) into 96-well microti- 
ter plates (lmmulon IV; Dynatech Laboratories, Inc., Chantilly, 
VA) that had been precoated with either mAb BVD4-1Dll .2 
against IL-4 or mAb 1L46A2 against IFN-% Serial threefold ilu- 
1Abbreviations u ed in this paper: Ach, acetylcholine chloride; BAL, bron- 
choalveolar lavage; ELISPOT, enzyme-hnked immunospot assay; FBS, 
fetal bovine serum: HPILT, hypoxanthine phospboribosyl transferase. 
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tions were prepared, and the plates were incubated undisturbed 
for 8 h at 37~ Wells were washed with PBS to remove cells and 
incubated with biotinylated secondary antibodies against IL-4 
(BVD6-24G.2) or [FN-~ (XMG-1.2). After 1 h, wells were 
washed and incubated for 1 h with 100 ~1 ofstreptavidin-conju- 
gated alkaline phosphatase (Jackson ImmunoResearch Laborato- 
ries, Inc., West Grove, PA) in PBS with 0.05% Tween 20 and 
5% FBS. Color was developed with 5-bromo-4-chloro-3- 
indolyl phosphate in 0.1 M 2-amino-2-methyl-l-propanol buffer 
(Sigma Chemical Co.) suspended in 0.6% agarose (Sea-Plaque; 
FMC Bioproducts Inc., Rockland, ME). After solidification of 
the agar, individual blue spots were counted by inverted micros- 
copy. 
Antibody Isotypes. Total serum IgE was quantitated using a 
double mAb-based sandwich ELISA with antibody B.IE.3 as the 
primary antibody and biotinylated EM-95 as the detecting anti- 
body. Results were quantitated by comparison to a standard con- 
trol (Sigma Chemical Co.). 
Histopathology. Whole lungs were distended by instillation of 
4% paraformaldehyde in PBS via the trachea, removed, and im- 
mersed in the same fixative with the trachea clamped for 24 h. 
Tissue was sliced and embedded in paraffin, and 5-lxm sections 
were stained with hematoxylin and eosin for light microscopic 
examination. 
Results 
Establishing a Murine Model of Airway Hyperreactivity. 
Groups of  BALB/c mice that had been immunized with 
OVA were challenged with aerosolized OVA, an irrelevant 
antigen, or saline; an additional nonimmunized group was 
challenged with aerosolized OVA. 1 d after the final aero- 
solization, mice were anesthetized and paralyzed, and, after 
stabilization on a rodent ventilator, airway pressure and re- 
sistance were measured after intravenous administration of  
1 ~g/g Ach (Fig. 1). Mice immunized with OVA and 
aerosolized with OVA demonstrated a marked broncho- 
motor response to Ach and a marked delay in the return to 
baseline airway pressure that was not present in any of  the 
other groups. To assess airway responsiveness by an alterna- 
tive method, airway resistance was measured and compared 
with simultaneously calculated airway pressure responses 
(Fig. 2). High doses of  Ach could elicit exaggerated bron- 
chomotor eactivity as assessed by increases in both airway 
pressure and resistance in control groups of  mice. How-  
ever, the dose-response curves were significantly shifted in 
the immunized group challenged with OVA (PCs0:1.7 • 
0.2 and PC200:1 .8  • 0.3 Ixg/g) compared with saline 
(PCs0:6.5 • 1.7 and PC200:6.2 • 0.8 p~g/g; P = 0.003 
and 0.03, respectively). Baseline values of  airway pressure 
and resistance did not differ significantly between groups of  
mice before injection of  Ach. These physiologic findings 
were reproducible in multiple experiments and were used 
to define antigen-specific airway hyperreactivity. Results in 
the subsequent experiments are displayed as airway pressure 
changes in response to 1 I~g/g Ach. 
The requirement for antigen specificity suggested by 
these experiments was consistent with a role for cells of  the 
acquired immune system. Immunization and aerosolization 
of  SCID mice, which are deficient in T and B cells, re- 
111 Corry et al. 
%Changefrom 
baseline 
Ach 
BALB~ 10.3 
NAIVE 
~//' I 
BALB/c 88.5 
OVA/OVA 
25.0 
BALB/c 
SALINEIOVA ~ ~ ,  33.3 
sco 
OVA/OVA 
F igure  1. Airway pressure tracings in response to Ach. BALB/c or 
SCID mice were untreated (naive), immunized with OVA (OVA) and 
aerosolized with OVA (OVA~OVA), immunized with OVA and aero- 
sohzed with an irrelevant antigen (OVA/irrelevant Ag), or immunized 
with saline and aerosolized with OVA (saline~OVA). After stabilization of 
airway pressures on a rodent ventilator, Ach (1 ~,g/g) was infused intrave- 
nously and the airway pressure changes continuously monitored. The 
time of Ach administration is indicated by the arrowhead. The maximum 
percent change in airway pressure relative to baseline is indicated on the 
right of the tracings. Results are representative of five experiments with 
three to five animals per group. 
sulted in no induction of  airway reactivity to Ach under 
the same conditions (Fig. 1). 
Characterization fthe Cellular Response Accompanying Air- 
way Hyperreactivity. Having established a model o f  airway 
hyperreactivity, we next characterized the cells recruited to 
the lung and airways after antigen challenge (Table 1). 
Analysis of  the cells in BAL and whole lung confirmed the 
marked increase in total cells, particularly eosinophils and 
.~ A 
100 "J ~ OVA/SALINE ]" 
0v%4 
"1 
"1 
o! y , , ,  , , 
o., ,.0  .3,0.0 
Dose Ach, microgramfdg 
B 
I - -o- -  OWSALIN~ r 
0.1 0 .32  1.0 3.3 10.8 
De~r Ach, micrograms/g 
Figure 2. Dose-response curves to intravenous Ach. Groups of five 
BALB/c mice were immunized with OVA and challenged with either 
OVA (solid circles) or saline (open circles) aerosol. Airway pressure (A) and 
resistance (B) were quantitated asdescribed in the Materials and Methods. 
Results represent mean + SEM and are representative of two separate x- 
periments. 
Table 1. Cellular Response and Maximal Airway Pressure to Ach in Designated Experimental Groups 
Total Cells Eosinophil PMN Lymphocyte Mono/Macro 
Airway 
Group BAL Lung BAL Lung BAL Lung BAL Lung BAL Lung Pressure 
X 106 % cm H2 0 
Experiment 1
Sham/OVA ND 0.74 0 0.7 0 0.4 1.0 20.0 99.0 79.0 6 + 2 
OVA/sham 0.25 1.3 0 1.9 0 1.5 0 24.0 99.0 73.0 10 + 4 
OVA/OVA 2.7 5.6 63.0 20.0 2.8 0.8 9.2 30.0 25.0 49.0 36 + 3 
Experiment 2
OVA/OVA + anti-IL-5 1.0 3.0 1.9 0.85 1.4 18.0 11.0 30.0 86.0 43.0 22 + 8.8 
OVA/OVA 5.0 7.0 44.0 23.0 1.1 8.8 18.0 39.0 37.0 29.0 22 + 7.7 
Mice in the designated groups were killed 1 d after the final aerosol challenge, and BAL and total lung cells were purified as described in Materials 
and Methods. The percentages of the designated cell types w re highly comparable in two separate xperiments and were derived from pooled cells 
representing five mice in each group. Maximal airway pressure change i  r sponse to 1 p,g Ach/g mouse was quantitated as described in Materials 
and Methods and is expressed asmean + SEM. 
lymphocytes, in animals that were both immunized and 
aerosolized with OVA.  Lymphocyte recruitment in BAL 
was biased toward CD4 + T cells, as demonstrated by eleva- 
t ion of  the CD4+/CD8 + cell ratio as assessed by cytofluori-  
metric analysis (CD4+/CD8 + = 2.7 for sham aerosol, 6.1 
for OVA).  Light microscopy o f  fixed lung specimens re- 
vealed a lymphocyt ic  infdtrate with numerous eosinophils 
around veins and bronchoarterial bundles in immunized 
and aerosolized mice that was not  present in control ani- 
mals (Fig. 3). 
Cytokine Expression in Mice with Airway Hyperreactivity. 
Cytokine expression by immune cells recruited to the lungs 
Figure 3. Histology of the lung in immunized mice. (A) BALB/c mouse immunized with OVA subcutaneously and aerosolized with OVA. Note 
marked peribronchovascular infiltrates. (B) BALB/c mouse immunized with OVA subcutaneously and aerosolized with saline, v, vessel; b, bronchiole. 
Hemotoxylin and eosin stained sections. • (A); • (B). 
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Figure 4. Cytokine transcripts from BAL cells of 
BALB/c mice immunized with OVA and chal- 
lenged with aerosol saline (lane 1), immunized with 
saline and challenged with aerosol OVA (lane 2), or 
immunized with OVA and challenged with aerosol 
OVA (lane 3). Concentrations of input cDNA 
were standardized by equalizing amplification of 
the constitutively xpressed HPRT transcript by 
use of a polycompetitor construct containing tan- 
demly arrayed amplification products that contain 
an irrelevant insert enlarging theirsize such that 
they migrate more slowly in ethidium bromide- 
stained agarose gels. After standardizing HPRT 
products, cytokine transcripts were amplified and compared by quantitat- 
ing amplification fthe wild-type (lower band for each amplification prod- 
uct) and the competitor (upper band for each product) products using im- 
aging densitometry. Results are representative of three independent 
experiments. 
of  mice with airway hyperreactivity was quantitated using 
both tLNA- and protein-based assays. Using a competitive 
reverse transcription-PCR, approach, transcripts for IL-4, 
IL-5, IL-10, and IL-13, and to a lesser extent, IFN-',/, were 
substantially induced in mice that had been both immu- 
nized and aerosolized with OVA (Fig. 4). IFN-y,  but not 
the Th2 cytokines, was induced by aerosol alone, even in 
nonimmunized mice. ELISPOT assays were performed im- 
mediately after removing cells from the lung in the absence 
of added antigen in vitro to assess pontaneous cytokine 
production. Mice immunized and aerosolized with OVA 
had 2- to 3-fold increases in numbers of  IFN-',/-secreting 
cells and 200-fold increases in the numbers of  IL-4-secret- 
ing cells per lung compared with nonimmunized mice that 
received aerosolized OVA (Table 2). The marked elevation 
in IL-4 production was consistent with the significantly 
raised levels of  serum IgE in mice immunized with OVA 
(nonimmunized BALB/c mice: <1 ~g/ml; immunized 
BALB/c mice: 10 + 0.8 Dg/ml; P <0.05). Treatment with 
GK1.5, a mAb that depletes CD4 + T cells in vivo, during 
the period of  aerosolization of  OVA completely abrogated 
the induction o fTh2  cytokines (data not shown). 
Effects of Cytokine Neutralization on Airway Hyperreactivity, 
Cell Recruitment, and Cytokine Expression. To elucidate the 
role of  IL-5 and eosinophils, mice were given two neutral- 
izing anti-lL-5 mAbs weekly beginning with the first sub- 
cutaneous immunization with OVA; isotype-matched con- 
trol antibodies were given to controls. Despite substantial 
reduction in eosinophil numbers in BAL and whole lung, 
in some animals to <1%, airway pressures of mice treated 
with anti-IL-5 were not substantially different han animals 
that received isotype-matched antibodies (Fig. 5). Abroga- 
tion of  eosinophil infiltration into the lung in mice treated 
with anti-IL-5 antibodies was corroborated by enumera- 
tion of  BAL and isolated lung cells (Table 1) and by light 
microscopic examination of  fixed tissue sections (data not 
shown). 
In marked contrast o mice treated with anti-IL-5, mice 
treated with neutralizing anti-IL-4 mAb throughout he 
period of  immunization had substantial blockade of airway 
hyperreactivity (Fig. 6 A). Treatment of  mice with anti- 
IL-4 had little effect on levels of  eosinophils in the lung, 
suggesting that the effects of  IL-4 are independent of effects 
on eosinophils, in agreement with earlier studies using dif- 
ferent models (25). Importantly, when anti-IL-4 was given 
only during the period of  aerosolization of  OVA, and not 
during the subcutaneous priming period, there was no ef- 
fect on airway hyperreactivity (Fig. 6 B). 
Comparison of Airway Hyperreactivity between BALB/c and 
C57BL/6 Mice. The results using anti-IL-4 suggested that 
production of  IL-4 early, during the period o fT  cell prim- 
ing, was critically associated with the later manifestation of  
airway hyperreactivity. BALB/c mice, compared with 
C57BL/6 animals, produce enhanced amounts of  IL-4 dur- 
ing priming of CD4 + T cells (26), a characteristic that may 
underlie the peculiar susceptibility of  BALB/c mice to 
L. major (27). If production of  IL-4 during initial antigen 
exposure is associated with airway hyperreactivity in this 
model, BALB/c mice might be expected to generate in- 
creased responses compared with other strains of  mice. In 
side-by-side comparisons of similarly treated animals, BALB/c 
Table 2. Cytokine Protein Production of Isolated Whole-Lung Cells from OVA-immunized an  -aerosolized Mice 
Cytokines 
IFN-'y IL-4 
Group Cell frequency Total cells/lung Cell frequency Total cells/lung 
per 106 cells per 106 cells 
OVA/OVA 61 + 31 376 +_ 221 265 + 49 1929 + 514 
OVA/irrelevant Ag 25 + 5.8 35 + 13 77 • 13 96 + 10 
Sham/OVA 320 128 24 9.6 
Mice in the designated groups were killed 1 d after the final aerosol challenge. Purified lung cells we e assessed for spontaneous secretion of IFN-~ 
and IL-4 using an ELISPOT assay as described in Materials and Methods. Data represent mean -+ SEM from three animals and are representative of 
three separate experiments. 
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Figure 5. Effect of IL-5 neutralization bronchial hyperreactivity. 
Groups of BALB/c mice were immunized with OVA and challenged 
with OVA or saline aerosol. Designated groups were treated weekly with 
neutralizing anti-IL-5 or isotype control antibodies throughout the ex- 
perimental protocol. Results are expressed asmean maximum percentage 
of change in airway pressure -+ SEM relative to baseline after chal]enge 
with intravenous Ach and are representative of two comparable experi- 
ments. Percentages ofeosinophils n recovered BAL cells are depicted be- 
neath the bar graphs (% Eo). 
mice demonstrated consistently greater airway hyperreac- 
tivity than did C57BL/6 (percent change in baseline airway 
pressure 30 -+ 6 versus 7 + 3 for BALB/c versus C57BL/6, 
respectively; P <0.05). 
Discussion 
The presence of activated T cells in bronchial biopsies 
and BAL fluid from patients with asthma (3-6, 28, 29) and 
of  lymphocytes in the airways and submucosa of patients 
dying of  the disease (30, 31) have focused attention on the 
role of  cells of  the acquired immune system in the patho- 
genesis of  asthma. Activated CD4 + T cells have been re- 
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Figure 6. Effect of IL-4 neutralization bronchial hyperreactivity. 
Groups of BALB/c mice were immunized with OVA and challenged 
with OVA or saline aerosol. Designated groups were treated weekly 
throughout the experiment with neutralizing anti-IL-4 antibody or iso- 
type control (A) or only during the period of aerosol challenge (B). R_e- 
suits are expressed asmean maximum percentage of airway pressure -+ 
SEM relative to baseline after challenge with intravenous Ach and are 
representative of two comparable experiments. Percentages ofeosinophils 
in recovered BAL cells are depicted beneath t e bar graphs (% Eo). 
covered that express a range of cytokines, particularly IL-4, 
IL-5, and GM-CSF, consistent with a Th2-1ike profile (3-6). 
Allergen-specific T cell clones established from atopic indi- 
viduals consistently produce Th2 cytokines (32), and aller- 
gen-induced provocation has caused expression of  these 
cytokines at sites of  challenge (33, 34). Although activated 
T cells constitute a significant source of  these cytokines, 
both activated mast cells (35, 36) and eosinophils (37) are 
capable of  contributing Th2-1ike cytokines that might be 
anticipated to compound pathology mediated by these cy- 
tokines in an autocrine fashion. Patients have been identi- 
fied with expanded numbers of  Th2-1ike cells or clones 
who present with atopic symptoms, including sinopulmo- 
nary pathology (38, 39). These various data have suggested 
a model of  asthma in which aberrant activation of  immune 
cells to produce Th2-type cytokines in response to un- 
known respiratory antigens leads to the recruitment of  mast 
cells, T cells, and eosinophils capable of  causing chronic 
damage to the airway. 
The murine model used in these studies constitutes a re- 
producible system for inducing airway hyperreactivity in
response to antigen that permits the identification of  factors 
that are required for this physiologic response. As demon- 
strated using SCID mice, the phenotype of airway hyperre- 
activity required cells of  the specific immune system. Stud- 
ies elsewhere have demonstrated that depletion of T cells, 
or CD4 + T cells, up to 1 wk before challenge successfully 
abrogated the airway response (11, 18). As shown here, 
IL-4 was required during the period of  T cell priming to 
OVA, since neutralization of  IL-4 abrogated the physio- 
logic response when administered uring subcutaneous 
sensitization with antigen, but not during the period of  
aerosol challenge. A number of in vitro and in vivo systems 
have demonstrated that IL-4 is required for the priming of  
Th2 cells (40), suggesting that CD4 + T cell priming with 
IL-4 is a prerequisite for the development of  airway inflam- 
mation and hyperreactivity o Ach. Similar results were ob- 
served in studies using IL-4 knock-out mice; airway in- 
flammation and bronchial responses to carbachot and 
serotonin were substantially less than in wild-type mice 
(41). The results here would extend those findings to a 
greater equirement for IL-4 in the inductive, rather than 
effector, stages of  airway pathology, despite the fact that we 
were able to quantitate marked production of  IL-4 during 
the time that bronchial hyperreactivity was determined. 
A large body of literature has documented the associa- 
tion of  pulmonary eosinophil infiltration and airway hyper- 
reactivity in both asthmatic humans and animal models of  
airway inflammation (1, 9, 42). Studies from humans with 
asthma have demonstrated large quantities of  eosinophil 
cationic protein and major basic protein in BAL fluid and 
deposited in the submucosa of  airway biopsies, indicating 
active eosinophil degranulation (9, 42). Eosinophil prod- 
ucts are postulated to contribute to airway hyperreactivity 
through damage to the airway epithelium, leaving underly- 
ing smooth muscle more susceptible to nonspecific on- 
tractile mediators, or perhaps by contributing to the airway 
remodeling and narrowing observed in patients with 
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chronic disease (43, 44). Although a role for eosinophils in 
contributing to chronic airway changes or late-phase asth- 
matic responses i not excluded, the data here do not sup- 
port a role for either IL-5 or eosinophils in mediating the 
acute airway hyperreactivity seen in this model. Studies of  
intestinal helminth infection, another system in which eosi- 
nophils are prevalent, have also been unable to define a role 
for eosinophils in mediating either host defense or patho- 
logic responses (45). 
The demonstration that IL-4 was required at the time of 
parenteral sensitization but not at the time of  challenge 
leaves unanswered the source of  the early IL-4 and the 
mechanism by which airway effects are mediated. Transfer 
of  wild-type CD4 + T cells into IL-4 knock-out mice sug- 
gested that CD4 + T cells themselves were capable of  gen- 
erating the IL-4 required for Th2-1ike responses in the ab- 
sence of mast cells or basophils (46). Recent studies have 
focused attention on a subset of  CD4 + T cells restricted by 
nonpolymorphic lass I molecules, including CD1 (47), 
that generated essentially all of  the IL-4 produced after ad- 
ministration of  anti-CD3 or superantigens (48). These T 
cells show a marked bias toward expression of  V[38 T cell 
receptors (49). Interestingly, V]38 + T cells were demon- 
strated both to expand after immunization of  BALB/c mice 
with OVA and to be capable of  transferring airway hyper- 
reactivity to naive recipients (50), raising the possibility that 
this unusual CD4 + T cell population might contribute to 
the development of  airway hyperreactivity. 
The effects of  neutralization of  IL-4 during the aerosol 
phase of  the model suggests that IL-4 is not required during 
the effector phase of  airway hyperreactivity. IL-4 is re- 
quired for IgE isotype switching, and cross-linking of  Fce 
receptors on mast cells by IgE would be consistent with the 
activated mast cell phenotype seen in asthma. Indeed, the 
mast cell-deficient W/W ~ mouse had diminished eosino- 
phil infltration when used in a comparable airway model 
(13). However, IgE-deficient mice were capable of  devel- 
oping anaphylaxis and pulmonary function changes compa- 
rable to wild-type mice (51), suggesting additional path- 
ways capable of mediating pathologic responses. The 
critical role for IL-4 during antigen priming in establishing 
the downstream cascade required for airway hyperreactivity 
suggests that interdictions capable of reprogramnfing CD4 + 
subset development to common respiratory allergens might 
constitute effective vaccine approaches to the control of  
asthma. Such interventions are amenable to testing in the 
animal model used for these studies. 
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